Top of this page
Skip navigation, go straight to the content

Investors UCB equity story

Since 2015, UCB has embarked on a very important change journey:

the Patient Value Strategy

In 2019 we entered the next phase of our Patient Value Strategy:

“Accelerate & Expand” (2019-2022)


During this phase, we are accelerating our growth potential by further improving our ability to demonstrate differentiation of our medicines, by accelerating our development timelines through new approaches and by improving patients’ access to our key medicines.

The evolving COVID-19 pandemic is profoundly impacting our lives, and places tremendous strain on healthcare systems and society at large. Since the start of the crisis, UCB has taken measures to protect our colleagues around the world, to stand by patients, to help our communities and take our part in the global response to the pandemic. We know that it is our responsibility to help where we can make an impact. Find out what actions UCB as taken here.

We have made significant progress towards this ambitious goal


Accelerate & expand - deliverables


2019 achievements

  • Evenity® (romosozumab) and Nayzilam® (midazolam) were approved and launched as planned.
  • bimekizumab delivered three positive Phase 3 study results in psoriasis; submission to regulatory bodies should occur  mid-2020.
  • UCB started multiple Phase 3 studies: bimekizumab in psoriatic arthritis, axial spondyloarthitis and hidradenitis suppurativa (early 2020), padsevonil in drug resistant epilepsy and rozanolixizumab in generalized myasthenia gravis as well as in immune thrombocytopenia.
  • UCB0107, our anti-Tau antibody, reported positive Phase 1 results and will enter the confirmatory study.

2020 so far...

  • rozanolixizumab Phase 3 started in ITP, Immune ThrombocytoPenia (Jan)  
  • bimekizumab Phase 3 was initiated in a 4th indication: hidradenitis suppurativa (Feb)  
  • padsevonil Phase 2b reported topline results (March)  
  • UCB finalized the acquisition of Ra Pharma (April)  
  • UCB acquires world-wide rights to Staccato® Alprazolam (June)
  • bimekizumab Phase 3 data (BE VIVID & BE READY studies) in psoriasis presented at AAD (June)

Our key medicines

We bring solutions to people living with neurological or immunological diseases.

Serving patients, our key medicines continued their growth in 2019.



Peak sales guidance


  • Cimzia® > € 2 billion by 2024  
  • Vimpat® > € 1.5 billion by 2022  
  • Briviact® > € 600 million by 2026
  • Neupro® ~ current level  
Keppra® reached peak sales of € 1.2 billion in 2008.




Keppra logo


Our pipeline

In a challenging environment, our pipeline builds the basis of UCB’s sustainable long term growth.

To create a pipeline that will make a real difference in people’s lives, we focus on our key assets: our expertise in small and large molecules and our expertise in the fields of neurology and auto-immune diseases.

Up to 7 potential product launches* by 2025

  • Romosozumab in severe osteoporosis (launched in 2019)
  • Midazolam nasal spray in acute repetitive epilepsy seizures (launched in 2019)
  • Bimekizumab in psoriasis, psoriatic arthritis, axial spondyloarthritis and hidradenitis suppurativa
  • Rozanolixizumab in Immune ThrombocytoPenia, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy 
  • Zilucoplan in general Myasthenia Gravis
  • Staccato® alprazolam in acute epileptic seizure
  • Anti-Tau in progressive supranuclear palsy


* subject to approval

Clinical studies index

UCB is committed to sharing information on studies and making study results publicly accessible. You will find below links to the clinical studies (Phase 2-4) of our main R&D projects.

More information about our clinical studies index and our position paper are available here.


UCB pipeline

June 2020

CIDP: Chronic Inflammatory Demyelinating Polyneuropathy  

IMNM: Immune-Mediated Necrotizing Myopathy  

ARDS: acute respiratory distress syndrome 

  1. In partnership with HEALEY ALS Platform Trial
  2. In partnership with University of Ghent (Belgium) & Medical Research Council (U.K.)
  3. In partnership with Biogen




Contact the IR team and we will do our best to help you!